Wine, Alcohol, and Cardiovascular Health: Revisiting the Health Benefits of Wine in the Framingham Heart Study. Michael Darden and Douglas Nelson

Size: px
Start display at page:

Download "Wine, Alcohol, and Cardiovascular Health: Revisiting the Health Benefits of Wine in the Framingham Heart Study. Michael Darden and Douglas Nelson"

Transcription

1 Wine Alcohol and Cardiovascular Health: Revisiting the Health Benefits of Wine in the Framingham Heart Study. Michael Darden and Douglas Nelson May 28th 2015

2 Outline Background Our Approach Framingham Heart Study Descriptive Analysis Application - Smoking AWEA Wine and Health 05/28/2015 2

3 Does Everything We Consume Cause Cancer? AWEA Wine and Health 05/28/2015 3

4 Does Everything We Consume Cause Cancer? AWEA Wine and Health 05/28/2015 3

5 Why is it difficult? Assessing the long-term health effects of alcohol consumption is difficult because: AWEA Wine and Health 05/28/2015 4

6 Why is it difficult? Assessing the long-term health effects of alcohol consumption is difficult because: 1. Many major health outcomes occur far in the future. AWEA Wine and Health 05/28/2015 4

7 Why is it difficult? Assessing the long-term health effects of alcohol consumption is difficult because: 1. Many major health outcomes occur far in the future. 2. Ideally the difference in major health outcomes should be calculated from observed health differences following random assignment of lifetime drinking behavior. AWEA Wine and Health 05/28/2015 4

8 Why is it difficult? Assessing the long-term health effects of alcohol consumption is difficult because: 1. Many major health outcomes occur far in the future. 2. Ideally the difference in major health outcomes should be calculated from observed health differences following random assignment of lifetime drinking behavior. In reality researchers must use observational data. AWEA Wine and Health 05/28/2015 4

9 What is typically done? 1. Difference in Means Simple and transparent Ignores potential heterogeneity AWEA Wine and Health 05/28/2015 5

10 What is typically done? 1. Difference in Means Simple and transparent Ignores potential heterogeneity For example: Doll et al British Medical Journal study the effect of smoking on expected longevity AWEA Wine and Health 05/28/2015 5

11 What is typically done? 1. Difference in Means Simple and transparent Ignores potential heterogeneity For example: Doll et al British Medical Journal study the effect of smoking on expected longevity Confounding factors are unlikely to have influenced greatly the absolute difference between the overall mortality rates of cigarette smokers and lifelong non-smokers - Doll et al British Medical Journal AWEA Wine and Health 05/28/2015 5

12 What is typically done? 2. Controlling for observed heterogeneity. Conditional estimates of health impact. Biased if unobserved factors influence both lifestyle behavior and health outcomes AWEA Wine and Health 05/28/2015 6

13 What is typically done? 2. Controlling for observed heterogeneity. Conditional estimates of health impact. Biased if unobserved factors influence both lifestyle behavior and health outcomes For example: Djoussee et al Stroke study the effect of alcohol consumption on the risk of Ischemic Stroke AWEA Wine and Health 05/28/2015 6

14 What is typically done? 2. Controlling for observed heterogeneity. Conditional estimates of health impact. Biased if unobserved factors influence both lifestyle behavior and health outcomes For example: Djoussee et al Stroke study the effect of alcohol consumption on the risk of Ischemic Stroke The full model controlled for age diabetes mellitus(yes/no) smoking categories and body mass index. AWEA Wine and Health 05/28/2015 6

15 Our Approach AWEA Wine and Health 05/28/2015 7

16 Our Approach Consider the following question: How many years of expected longevity are lost from heavy alcohol consumption? AWEA Wine and Health 05/28/2015 7

17 Our Approach Consider the following question: How many years of expected longevity are lost from heavy alcohol consumption? We argue this question is difficult to answer because: 1. Lifetime drinking patterns reflect choices of individuals who differ in observed and unobserved ways. That is alcohol consumption is not random. AWEA Wine and Health 05/28/2015 7

18 Our Approach Consider the following question: How many years of expected longevity are lost from heavy alcohol consumption? We argue this question is difficult to answer because: 1. Lifetime drinking patterns reflect choices of individuals who differ in observed and unobserved ways. That is alcohol consumption is not random. 2. Drinkers and nondrinkers may differ in observed and unobserved ways that contribute to mortality. That is confounding factors influence health outcomes. AWEA Wine and Health 05/28/2015 7

19 Our Approach Consider the following question: How many years of expected longevity are lost from heavy alcohol consumption? We argue this question is difficult to answer because: 1. Lifetime drinking patterns reflect choices of individuals who differ in observed and unobserved ways. That is alcohol consumption is not random. 2. Drinkers and nondrinkers may differ in observed and unobserved ways that contribute to mortality. That is confounding factors influence health outcomes. Because random assignment is not possible we argue that important qualities of observational data should include: A long longtudinal study design. Frequent interviews/exams. Rich observable heterogeneity AWEA Wine and Health 05/28/2015 7

20 Outline Background Our Approach Framingham Heart Study Descriptive Analysis Application - Smoking AWEA Wine and Health 05/28/2015 8

21 The Framingham Heart Study AWEA Wine and Health 05/28/2015 9

22 The Framingham Heart Study The Original Cohort Begun in 1948 to identify the common factors that contribute to cardiovascular disease. Sampled 5209 individuals from Framingham MA and followed them for over 50 years. Detailed health information. Fairly consistent alcohol information. Ages range from 30 to 63 at the initial exam (between 1948 and 1953). The Offspring Cohort: Offspring of the Original Cohort began begin followed in 1971 Sample of 5124 people between ages of 13 and 62 Health examinations/interviews every 2-8 years. AWEA Wine and Health 05/28/2015 9

23 Sample Construction Beer wine and spirits (drinks per week) was recorded at exams: Original Cohort: Offspring Cohort: 1-7 AWEA Wine and Health 05/28/

24 Sample Construction Beer wine and spirits (drinks per week) was recorded at exams: Original Cohort: Offspring Cohort: 1-7 In addition to a variety of biomarkers measured in each exam we have dates for the following health events: Coronary Heart Disease Myocardial Infarction Angina Pectoris Coronary Insufficiency Cerebrovascular Accident Atherothrombotic Infarction Transient Ischemic Attack Cardiovascular Disease Intermittant Claudication Congestive Heart Failure etc. A wide variety of cancers. Death AWEA Wine and Health 05/28/

25 Sample Construction Beer wine and spirits (drinks per week) was recorded at exams: Original Cohort: Offspring Cohort: 1-7 In addition to a variety of biomarkers measured in each exam we have dates for the following health events: Coronary Heart Disease Myocardial Infarction Angina Pectoris Coronary Insufficiency Cerebrovascular Accident Atherothrombotic Infarction Transient Ischemic Attack Cardiovascular Disease Intermittant Claudication Congestive Heart Failure etc. A wide variety of cancers. Death We pool data from both cohorts and after restricting our sample such that a person enters at least twice we have 7454 unique individuals and person/exam observations AWEA Wine and Health 05/28/

26 Table: Summary Statistics - Exogenous Characteristics Original Cohort Offspring Cohort Variable Mean St. Dev Mean St. Dev Female College Age Body Type BMI< BMI [2025) BMI [2529) BMI [3035) BMI> BMI Missing Systolic Blood Pressure Total Cholesterol Missing Currently Smoke Years Smoking AWEA Wine and Health 05/28/

27 Table: Summary Statistics - Alcohol Original Cohort Offspring Cohort Variable Mean St. Dev Mean St. Dev Drinks Wine Glasses/week Drinks Beer Beers/week Drinks Spirits Beers/week AWEA Wine and Health 05/28/

28 Drinks by Age 60 Drinks Alcohol by Type and Age 40 Percent Age Drinks Wine Drinks Spirits Drinks Beer AWEA Wine and Health 05/28/

29 Drinks/Week by Age 10 Drinks per week by Type and Age 8 Drinks/week Age Wine Spirits Beer AWEA Wine and Health 05/28/

30 Original Cohort Health Events 40 Health Events by Observation - Original Cohort 30 Percent Observation Cardiovascular Disease Cancer AWEA Wine and Health 05/28/

31 Offspring Cohort Health Events 15 Health Events by Observation - Offspring Cohort 10 Percent Observation Cardiovascular Disease Cancer AWEA Wine and Health 05/28/

32 Original Cohort Survival Kaplan-Meier Survival Curves - Original Cohort Age Drinker Never Drinker AWEA Wine and Health 05/28/

33 Offspring Cohort Survival Kaplan-Meier Survival Curves - Offspring Cohort Age Drinker Never Drinker AWEA Wine and Health 05/28/

34 Econometric Model Dynamic Panel Data Model. t subscript represents FHS exam time: Dependent Variables: 1. Drinks wine at t 2. Glasses per week drinking wine at t 3. Drinks beer at t 4. Beers per week drinking beer at t 5. Drinks Spirits at t 6. Cocktails per week drinking spirits at t 7. Cardiovascular Disease at t 8. Cancer at t 9. Death at t AWEA Wine and Health 05/28/

35 Econometric Framework AWEA Wine and Health 05/28/

36 Econometric Framework W it = w(a it 1 H it 1 X it P it u w it εw it ) AWEA Wine and Health 05/28/

37 Econometric Framework W it = w(a it 1 H it 1 X it P it u w it εw it ) H it = h(a it H it 1 X it μ h it εh it ) AWEA Wine and Health 05/28/

38 Econometric Framework W it = w(a it 1 H it 1 X it P it u w it εw it ) H it = h(a it H it 1 X it μ h it εh it ) M it = h(a it H it X it μ m it εm it ) AWEA Wine and Health 05/28/

39 Error Structure The error structure for equation j: μ i + ν t + ε it AWEA Wine and Health 05/28/

40 Error Structure The error structure for equation j: μ i + ν t + ε it The distribution of both time-invariant and time-varying unobserved heterogeneity terms μ i and ν t are approximated discretely. We estimate a step function for both: μ i takes A points: (μ 1... μ A ). ν t takes B points: (ν 1... ν B ). Subject to normalizations we estimate these points for each equation as well as the associated probabilities. AWEA Wine and Health 05/28/

41 Model Setup The model captures alcohol and health outcomes for up to 11 periods. Each period of the model is two years in length. W t M t W t 1 H t 1 M t 1 H t AWEA Wine and Health 05/28/

42 Logit Estimator Results Table: Selected Parameter Estimates CVD Cancer Mortality Wine Quartile Relative to No Wine Consumption 1st * (0.112) (0.149) (0.175) 2nd * (0.118) (0.146) (0.178) 3rd (0.099) (0.129) (0.133) 4th (0.120) (0.160) (0.158) Alcohol Quartile Relative to No Alcohol Consumption 1st ** ** (0.063) (0.094) (0.093) 2nd ** ** (0.071) (0.104) (0.108) 3rd ** ** (0.071) (0.105) (0.102) 4th ** ** (0.066) (0.090) (0.098) AWEA Wine and Health 05/28/

43 Simulation Exercise To simulate our model we: 1. Expand each person s observation by 50 AWEA Wine and Health 05/28/

44 Simulation Exercise To simulate our model we: 1. Expand each person s observation by Endow each with random draws from all error terms AWEA Wine and Health 05/28/

45 Simulation Exercise To simulate our model we: 1. Expand each person s observation by Endow each with random draws from all error terms 3. Simulate Behavior while updating state vector. In some cases we impose alcohol consumption and simulate health outcomes. 4. Collapse results by person draw and time. AWEA Wine and Health 05/28/

46 Survival Curves from the Framingham Heart Study Kaplan-Meier Survival Curves: Data Age Smoker Never Smoker Source: Authors Calculations from the Framingham Heart Study AWEA Wine and Health 05/28/

47 Mean Age of Death by Smoking Behavior Mean Age Mean Loss Never Smoker (8.81) - Current Smoker (10.10) AWEA Wine and Health 05/28/

48 Survival Curves from the Framingham Heart Study Kaplan-Meier Survival Curves: Data Age Smoker Never Smoker Source: Authors Calculations from the Framingham Heart Study AWEA Wine and Health 05/28/

49 Simulated Survival Curves by Lifetime Smoking Behavior Kaplan-Meier Survival Curves: Simulation Age Smoker Never Smoker Source: Authors Calculations AWEA Wine and Health 05/28/

50 Simulated Mean Age of Death by Smoking Behavior Mean Age Mean Loss Never Smoker Current Smoker AWEA Wine and Health 05/28/

51 Thank you! AWEA Wine and Health 05/28/

Consumption of different types of alcohol and mortality

Consumption of different types of alcohol and mortality Consumption of different types of alcohol and mortality 1 di 6 Results Consumption of different types of alcohol and mortality We know that a moderate amount of alcohol consumption is beneficial for health.

More information

Baldness and Coronary Heart Disease Rates in Men from the Framingham Study

Baldness and Coronary Heart Disease Rates in Men from the Framingham Study A BRIEF ORIGINAL CONTRIBUTION Baldness and Coronary Heart Disease Rates in Men from the Framingham Study The authors assessed the relation between the extent and progression of baldness and coronary heart

More information

I t is established that regular light to moderate drinking is

I t is established that regular light to moderate drinking is 32 CARDIOVASCULAR MEDICINE Taking up regular drinking in middle age: effect on major coronary heart disease events and mortality S G Wannamethee, A G Shaper... See end of article for authors affiliations...

More information

THE FRAMINGHAM STUDY Protocol for data set vr_soe_2009_m_0522 CRITERIA FOR EVENTS. 1. Cardiovascular Disease

THE FRAMINGHAM STUDY Protocol for data set vr_soe_2009_m_0522 CRITERIA FOR EVENTS. 1. Cardiovascular Disease THE FRAMINGHAM STUDY Protocol for data set vr_soe_2009_m_0522 CRITERIA FOR EVENTS 1. Cardiovascular Disease Cardiovascular disease is considered to have developed if there was a definite manifestation

More information

CVD Prevention, Who to Consider

CVD Prevention, Who to Consider Continuing Professional Development 3rd annual McGill CME Cruise September 20 27, 2015 CVD Prevention, Who to Consider Dr. Guy Tremblay Excellence in Health Care and Lifelong Learning Global CV risk assessment..

More information

Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors.

Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors. Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors. Appendix to: Banks E, Crouch SR, Korda RJ, et al. Absolute risk of cardiovascular

More information

Smoking and Mortality: New Evidence from a Long Panel

Smoking and Mortality: New Evidence from a Long Panel Smoking and Mortality: New Evidence from a Long Panel Michael Darden 1, Donna B. Gilleskie 2, and Koleman Strumpf 3 1 Department of Economics, Tulane University 2 Department of Economics, University of

More information

Update on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines

Update on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines Update on Lipid Management in Cardiovascular Disease: How to Understand and Implement the New ACC/AHA Guidelines Paul Mahoney, MD Sentara Cardiology Specialists Lipid Management in Cardiovascular Disease

More information

EuroPrevent 2010 Fatal versus total events in risk assessment models

EuroPrevent 2010 Fatal versus total events in risk assessment models EuroPrevent 2010 Fatal versus total events in risk assessment models Pekka Jousilahti, MD, PhD,Research Professor National Institute for Health and Welfare, Finland Risk assessment models Estimates the

More information

Lecture 8 Cardiovascular Health Lecture 8 1. Introduction 2. Cardiovascular Health 3. Stroke 4. Contributing Factors

Lecture 8 Cardiovascular Health Lecture 8 1. Introduction 2. Cardiovascular Health 3. Stroke 4. Contributing Factors Lecture 8 Cardiovascular Health 1 Lecture 8 1. Introduction 2. Cardiovascular Health 3. Stroke 4. Contributing Factors 1 Human Health: What s Killing Us? Health in America Health is the U.S Average life

More information

Smoking and Mortality: New Evidence from a Long Panel. Michael Darden, Donna B. Gilleskie, and Koleman Strumpf 1. August 2017.

Smoking and Mortality: New Evidence from a Long Panel. Michael Darden, Donna B. Gilleskie, and Koleman Strumpf 1. August 2017. Smoking and Mortality: New Evidence from a Long Panel Michael Darden, Donna B. Gilleskie, and Koleman Strumpf 1 August 2017 Abstract Many public health policies are rooted in findings from medical and

More information

Clinical Recommendations: Patients with Periodontitis

Clinical Recommendations: Patients with Periodontitis The American Journal of Cardiology and Journal of Periodontology Editors' Consensus: Periodontitis and Atherosclerotic Cardiovascular Disease. Friedewald VE, Kornman KS, Beck JD, et al. J Periodontol 2009;

More information

Wine Drinking and Risks of Cardiovascular Complications After Recent Acute Myocardial Infarction

Wine Drinking and Risks of Cardiovascular Complications After Recent Acute Myocardial Infarction Wine Drinking and Risks of Cardiovascular Complications After Recent Acute Myocardial Infarction Michel de Lorgeril, MD; Patricia Salen, BSc; Jean-Louis Martin, PhD; François Boucher, PhD; François Paillard,

More information

CONTRIBUTING FACTORS FOR STROKE:

CONTRIBUTING FACTORS FOR STROKE: CONTRIBUTING FACTORS FOR STROKE: HYPERTENSION AND HYPERCHOLESTEROLEMIA Melissa R. Stephens, MD, FAAFP Associate Professor of Clinical Sciences William Carey University College of Osteopathic Medicine LEARNING

More information

Module 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension

Module 2. Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension Module 2 Global Cardiovascular Risk Assessment and Reduction in Women with Hypertension 1 Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored,

More information

Hypertension and cardiovascular risk factors: intervention by the family physician

Hypertension and cardiovascular risk factors: intervention by the family physician Hypertension and cardiovascular risk factors: intervention by the family physician Hypertension is a common presentation and a known risk factor for cardiovascular disease. L H MABUZA MB ChB, BTh, MFamMed

More information

Setting The setting was primary care. The economic study was carried out in the UK.

Setting The setting was primary care. The economic study was carried out in the UK. Cost-effectiveness of rosuvastatin, atorvastatin, simvastatin, pravastatin and fluvastatin for the primary prevention of CHD in the UK Davies A, Hutton J, O'Donnell J, Kingslake S Record Status This is

More information

10/8/2018. Lecture 9. Cardiovascular Health. Lecture Heart 2. Cardiovascular Health 3. Stroke 4. Contributing Factor

10/8/2018. Lecture 9. Cardiovascular Health. Lecture Heart 2. Cardiovascular Health 3. Stroke 4. Contributing Factor Lecture 9 Cardiovascular Health 1 Lecture 9 1. Heart 2. Cardiovascular Health 3. Stroke 4. Contributing Factor 1 The Heart Muscular Pump The Heart Receives blood low pressure then increases the pressure

More information

Alcohol and Cancer: Defining the Exposure and Key Milestones in Establishing the Relationship

Alcohol and Cancer: Defining the Exposure and Key Milestones in Establishing the Relationship Alcohol and Cancer: Defining the Exposure and Key Milestones in Establishing the Relationship Susan M. Gapstur, PhD, MPH Vice President, Epidemiology American Cancer Society 1 Disclosure Information SUSAN

More information

Framingham Heart Study Longitudinal Data Documentation

Framingham Heart Study Longitudinal Data Documentation Framingham Heart Study Longitudinal Data Documentation The Framingham Heart Study is a long term prospective study of the etiology of cardiovascular disease among a population of free living subjects in

More information

Ischemic Heart Disease Mortality, Morbidity and Risk Factors of Coronary Care Unit Patients

Ischemic Heart Disease Mortality, Morbidity and Risk Factors of Coronary Care Unit Patients Ischemic Heart Disease Mortality, Morbidity and Risk Factors of Coronary (MBCHB, DM, FICMS) 1 Abstract Background: Ischemic heart disease (IHD) is the commonest type of heart disease.it causes more deaths

More information

2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary

2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary 2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease Becky McKibben, MPH; Seth

More information

Dyslipidemia in the light of Current Guidelines - Do we change our Practice?

Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease

More information

AHEAD - WAVE SECTION B - HEALTH - PAGE 6

AHEAD - WAVE SECTION B - HEALTH - PAGE 6 AHEAD - WAVE 1-1993 - SECTION B - HEALTH - PAGE 6 B1. Next I have some questions about your health. Would you say your health is excellent, very good, good, fair, or poor? 1.EXCELLENT 2.VERY GOOD 3.GOOD

More information

CVD risk assessment using risk scores in primary and secondary prevention

CVD risk assessment using risk scores in primary and secondary prevention CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities

More information

The value of stratified economic analysis in cohort-level models: A case study on interventions for obstructive sleep apnea

The value of stratified economic analysis in cohort-level models: A case study on interventions for obstructive sleep apnea The value of stratified economic analysis in cohort-level models: A case study on interventions for obstructive sleep apnea BERNICE TSOI AND KAREN LEE CADTH Disclosure No actual or potential conflict of

More information

7/6/2012. University Pharmacy 5254 Anthony Wayne Drive Detroit, MI (313)

7/6/2012. University Pharmacy 5254 Anthony Wayne Drive Detroit, MI (313) University Pharmacy 5254 Anthony Wayne Drive Detroit, MI 48202 (313) 831-2008 Be able to identify the signs of a heart attack or stoke Identify what puts you at a higher risk for cardiovascular disease,

More information

Drinking over the life-course and health effects. Annie Britton Alcohol Lifecourse Project University College London

Drinking over the life-course and health effects. Annie Britton Alcohol Lifecourse Project University College London Drinking over the life-course and health effects Annie Britton Alcohol Lifecourse Project University College London CLOSER 22 nd March 2018 H H H C C O H H H The UK Medical Research Council Alcohol Research

More information

LEADER Liraglutide and cardiovascular outcomes in type 2 diabetes

LEADER Liraglutide and cardiovascular outcomes in type 2 diabetes LEADER Liraglutide and cardiovascular outcomes in type 2 diabetes Presented at DSBS seminar on mediation analysis August 18 th Søren Rasmussen, Novo Nordisk. LEADER CV outcome study To determine the effect

More information

HIGH LDL CHOLESTEROL IS NOT AN INDEPENDENT RISK FACTOR FOR HEART ATTACKS AND STROKES

HIGH LDL CHOLESTEROL IS NOT AN INDEPENDENT RISK FACTOR FOR HEART ATTACKS AND STROKES HIGH LDL CHOLESTEROL IS NOT AN INDEPENDENT RISK FACTOR FOR HEART ATTACKS AND STROKES A study published in the British Medical Journal shows that not only is high LDL cholesterol not a risk factor for all-caused

More information

Lipid Management 2013 Statin Benefit Groups

Lipid Management 2013 Statin Benefit Groups Clinical Integration Steering Committee Clinical Integration Chronic Disease Management Work Group Lipid Management 2013 Statin Benefit Groups Approved by Board Chair Signature Name (Please Print) Date

More information

Northwestern University Feinberg School of Medicine Calculating the CVD Risk Score: Which Tool for Which Patient?

Northwestern University Feinberg School of Medicine Calculating the CVD Risk Score: Which Tool for Which Patient? Northwestern University Feinberg School of Medicine Calculating the CVD Risk Score: Which Tool for Which Patient? Donald M. Lloyd-Jones, MD, ScM, FACC, FAHA Senior Associate Dean Chair, Department of Preventive

More information

SDHU Population Health Profile. Summary Report

SDHU Population Health Profile. Summary Report SDHU Population Health Profile Summary Report Sudbury & District Health Unit Revised: January 29, 2016 Authors Michael King, Epidemiologist Dar Malaviarachchi, Epidemiologist Alissa Palangio, Data Analyst

More information

Is Knowing Half the Battle? Behavioral Responses to Risk Information from the National Health Screening Program in Korea

Is Knowing Half the Battle? Behavioral Responses to Risk Information from the National Health Screening Program in Korea Is Knowing Half the Battle? Behavioral Responses to Risk Information from the National Health Screening Program in Korea Hyuncheol Bryant Kim 1, Suejin A. Lee 1, and Wilfredo Lim 2 1 Cornell University

More information

Type of intervention Primary prevention; secondary prevention. Economic study type Cost-effectiveness analysis and cost utility analysis.

Type of intervention Primary prevention; secondary prevention. Economic study type Cost-effectiveness analysis and cost utility analysis. A predictive model of the health benefits and cost effectiveness of celiprolol and atenolol in primary prevention of cardiovascular disease in hypertensive patients Milne R J, Hoorn S V, Jackson R T Record

More information

Supplement materials:

Supplement materials: Supplement materials: Table S1: ICD-9 codes used to define prevalent comorbid conditions and incident conditions Comorbid condition ICD-9 code Hypertension 401-405 Diabetes mellitus 250.x Myocardial infarction

More information

Andrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION

Andrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION 2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL

More information

Tennessee Department of Health in collaboration with Tennessee State University and University of Tennessee Health Science Center

Tennessee Department of Health in collaboration with Tennessee State University and University of Tennessee Health Science Center Tennessee Department of Health in collaboration with Tennessee State University and University of Tennessee Health Science Center 2006 Tennessee Department of Health 2006 ACKNOWLEDGEMENTS CONTRIBUTING

More information

Statistical Fact Sheet Populations

Statistical Fact Sheet Populations Statistical Fact Sheet Populations At-a-Glance Summary Tables Men and Cardiovascular Diseases Mexican- American Males Diseases and Risk Factors Total Population Total Males White Males Black Males Total

More information

Smoking decreases the duration of life lived with and without cardiovascular disease: a life course analysis of the Framingham Heart Study

Smoking decreases the duration of life lived with and without cardiovascular disease: a life course analysis of the Framingham Heart Study European Heart Journal (24) 25, 49 45 Clinical research Smoking decreases the duration of life lived with and without cardiovascular disease: a life course analysis of the Framingham Heart Study Abdullah

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Clair C, Rigotti NA, Porneala B, et al. Association of smoking cessation and weight change with cardiovascular disease among people with and without diabetes. JAMA. doi:10.1001/jama.2013.1644.

More information

Cardiovascular Disease

Cardiovascular Disease Cardiovascular Disease Chapter 15 Introduction Cardiovascular disease (CVD) is the leading cause of death in the U.S. One American dies from CVD every 33 seconds Nearly half of all Americans will die from

More information

Essential Hypertension Management Considerations By Elaine Lewis, ND

Essential Hypertension Management Considerations By Elaine Lewis, ND Essential Hypertension Management Considerations By Elaine Lewis, ND Elaine Lewis, ND Research Resident, Canadian College of Naturopathic Medicine 1255 Sheppard Avenue East North York, Ontario Back To

More information

Biases in clinical research. Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University

Biases in clinical research. Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University Biases in clinical research Seungho Ryu, MD, PhD Kanguk Samsung Hospital, Sungkyunkwan University Learning objectives Describe the threats to causal inferences in clinical studies Understand the role of

More information

Cardiovascular Diseases and Diabetes

Cardiovascular Diseases and Diabetes Cardiovascular Diseases and Diabetes LEARNING OBJECTIVES Ø Identify the components of the cardiovascular system and the various types of cardiovascular disease Ø Discuss ways of promoting cardiovascular

More information

Analyzing diastolic and systolic blood pressure individually or jointly?

Analyzing diastolic and systolic blood pressure individually or jointly? Analyzing diastolic and systolic blood pressure individually or jointly? Chenglin Ye a, Gary Foster a, Lisa Dolovich b, Lehana Thabane a,c a. Department of Clinical Epidemiology and Biostatistics, McMaster

More information

What s new in cardiovascular disease risk assessment and management for primary care clinicians

What s new in cardiovascular disease risk assessment and management for primary care clinicians Cardiovascular system What s new in cardiovascular disease risk assessment and management for primary care clinicians The recently released 2018 Cardiovascular Disease Risk Assessment and Management for

More information

SEX LIES CHOLESTEROL

SEX LIES CHOLESTEROL SEX LIES and the CHOLESTEROL What You Don t Know Could Hurt You! TRUTH about Cardiovascular Disease Statistics Estimates for the year 2006 are that 81,100,000 people in the United States have one or more

More information

Comprehensive Tobacco Control Programs: Economic Review. Page 1 of 26. Study Info Intervention Characteristics Population Characteristics

Comprehensive Tobacco Control Programs: Economic Review. Page 1 of 26. Study Info Intervention Characteristics Population Characteristics Study Info Intervention Characteristics Population Characteristics Author, Year: Carter, 2000 Study design: Cost-effectiveness analysis Perspective: Commonwealth and Healthcare sector Location: Australia

More information

Moderate alcohol consumption is associated with decreased

Moderate alcohol consumption is associated with decreased Alcohol Consumption and Plasma Concentration of C-Reactive Protein Michelle A. Albert, MD, MPH; Robert J. Glynn, PhD; Paul M Ridker, MD, MPH Background Moderate alcohol intake has been associated with

More information

Comparison of Probability of Stroke Between the Copenhagen City Heart Study and the Framingham Study

Comparison of Probability of Stroke Between the Copenhagen City Heart Study and the Framingham Study 80 Comparison of Probability of Stroke Between the Copenhagen City Heart Study and the Framingham Study Thomas Truelsen, MB; Ewa Lindenstrtfm, MD; Gudrun Boysen, DMSc Background and Purpose We wished to

More information

Comparability of patient-reported health status: multi-country analysis of EQ-5D responses in patients with type 2 diabetes

Comparability of patient-reported health status: multi-country analysis of EQ-5D responses in patients with type 2 diabetes Comparability of patient-reported health status: multi-country analysis of EQ-5D responses in patients with type 2 diabetes Joshua A Salomon, Anushka Patel, Bruce Neal, Paul Glasziou, Diederick E. Grobbee,

More information

Intermediate Methods in Epidemiology Exercise No. 4 - Passive smoking and atherosclerosis

Intermediate Methods in Epidemiology Exercise No. 4 - Passive smoking and atherosclerosis Intermediate Methods in Epidemiology 2008 Exercise No. 4 - Passive smoking and atherosclerosis The purpose of this exercise is to allow students to recapitulate issues discussed throughout the course which

More information

Heart Disease and Stroke Statistics 2010 Update. 2009, American Heart Association. All rights reserved.

Heart Disease and Stroke Statistics 2010 Update. 2009, American Heart Association. All rights reserved. Heart Disease and Stroke Statistics 21 Update Questions on statistics? mailto:nancy.haase@heart.org Audio-visual questions? mailto:david.brentz@heart.org Please keep the red wave and logo attached to these

More information

ORIGINAL INVESTIGATION. Lifestyle and 15-Year Survival Free of Heart Attack, Stroke, and Diabetes in Middle-aged British Men

ORIGINAL INVESTIGATION. Lifestyle and 15-Year Survival Free of Heart Attack, Stroke, and Diabetes in Middle-aged British Men ORIGINAL INVESTIGATION Lifestyle and 15-Year Survival Free of Heart Attack, Stroke, and Diabetes in Middle-aged British Men S. Goya Wannamethee, PhD; A. Gerald Shaper, FRCP; Mary Walker, MA; Shah Ebrahim,

More information

An update on lipidology and cardiovascular risk management. Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine

An update on lipidology and cardiovascular risk management. Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine An update on lipidology and cardiovascular risk management Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine National and international lipid modification guidelines: A critical appraisal

More information

Risk modeling for Breast-Specific outcomes, CVD risk, and overall mortality in Alliance Clinical Trials of Breast Cancer

Risk modeling for Breast-Specific outcomes, CVD risk, and overall mortality in Alliance Clinical Trials of Breast Cancer Risk modeling for Breast-Specific outcomes, CVD risk, and overall mortality in Alliance Clinical Trials of Breast Cancer Mary Beth Terry, PhD Department of Epidemiology Mailman School of Public Health

More information

Albany County Health Profile

Albany County Health Profile 7/22/215 Albany County Health Profile Prepared By: www.hcdiny.org General Health: Albany Capital NYS, PA 217 County # Indicator Year(s) County Region except NYC Objective change needed For rate/% Rate/%

More information

Alcohol Consumption and Mortality in Serbia: Twenty-year Follow-up Study

Alcohol Consumption and Mortality in Serbia: Twenty-year Follow-up Study 45(6):764-768,2004 PUBLIC HEALTH Alcohol Consumption and Mortality in Serbia: Twenty-year Follow-up Study Branko Jakovljeviæ, Vesna Stojanov 1, Katarina Paunoviæ, Goran Belojeviæ, Nataša Miliæ 2 Institute

More information

lyondellbasell.com Managing Hypertension

lyondellbasell.com Managing Hypertension Managing Hypertension Managing Hypertension There is a growing evidence that the good health of your heart and circulation will help you to age more successfully. A man is as old as his arteries Thomas

More information

Examining the relationship between beverage intake and cardiovascular health. Ian Macdonald University of Nottingham UK

Examining the relationship between beverage intake and cardiovascular health. Ian Macdonald University of Nottingham UK Examining the relationship between beverage intake and cardiovascular health Ian Macdonald University of Nottingham UK Outline Assessment of evidence in relation to health risks of dietary components Cardiovascular

More information

Logistic Regression Predicting the Chances of Coronary Heart Disease. Multivariate Solutions

Logistic Regression Predicting the Chances of Coronary Heart Disease. Multivariate Solutions Logistic Regression Predicting the Chances of Coronary Heart Disease Multivariate Solutions What is Logistic Regression? Logistic regression in a nutshell: Logistic regression is used for prediction of

More information

Central pressures and prediction of cardiovascular events in erectile dysfunction patients

Central pressures and prediction of cardiovascular events in erectile dysfunction patients Central pressures and prediction of cardiovascular events in erectile dysfunction patients N. Ioakeimidis, K. Rokkas, A. Angelis, Z. Kratiras, M. Abdelrasoul, C. Georgakopoulos, D. Terentes-Printzios,

More information

Probabilistic Models for Heart Disease and Related Conditions

Probabilistic Models for Heart Disease and Related Conditions , July 5-7, 2017, London, U.K. Probabilistic Models for Heart Disease and Related Conditions Y. S. Yusoff., G Streftaris, H. R. Waters Abstract The mortality rates in the UK has changed over time. The

More information

HEALTH PROMOTION AND CHRONIC DISEASE PREVENTION PROGRAM OREGON STATE OF THE HEART AND STROKE REPORT 2001 PREPARED BY.

HEALTH PROMOTION AND CHRONIC DISEASE PREVENTION PROGRAM OREGON STATE OF THE HEART AND STROKE REPORT 2001 PREPARED BY. OREGON STATE OF THE HEART AND STROKE REPORT 2001 PREPARED BY THE OREGON DEPARTMENT OF HUMAN SERVICES HEALTH SERVICES HEALTH PROMOTION AND CHRONIC DISEASE PREVENTION PROGRAM www.healthoregon.org/hpcdp Contents

More information

I t is well established that non-insulin dependent diabetes is

I t is well established that non-insulin dependent diabetes is 1398 CARDIOVASCULAR MEDICINE Cardiovascular disease incidence and mortality in older men with diabetes and in men with coronary heart disease S G Wannamethee, A G Shaper, L Lennon... See end of article

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Leibowitz M, Karpati T, Cohen-Stavi CJ, et al. Association between achieved low-density lipoprotein levels and major adverse cardiac events in patients with stable ischemic

More information

ANNUAL FOLLOW-UP QUESTIONNAIRE

ANNUAL FOLLOW-UP QUESTIONNAIRE SLEEP HEART HEALTH STUDY - TUCSON ANNUAL FOLLOW-UP QUESTIONNAIRE - 2003 Dear Sleep Heart Health Study participant: Today s Date: / / Month Day Year Please take the time to complete and return this short

More information

Page down (pdf converstion error)

Page down (pdf converstion error) 1 of 6 2/10/2005 7:57 PM Weekly August6, 1999 / 48(30);649-656 2 of 6 2/10/2005 7:57 PM Achievements in Public Health, 1900-1999: Decline in Deaths from Heart Disease and Stroke -- United States, 1900-1999

More information

Date: / / Hello, my name is [interviewer name], and I'm calling to speak with [participant name]. Is [participant name] available?

Date: / / Hello, my name is [interviewer name], and I'm calling to speak with [participant name]. Is [participant name] available? Multi-Ethnic Study of Atherosclerosis Follow-up Phone Call 16 Participant Id#: Acrostic: General Health Date: / / Day INTRODUCTION Hello, my name is [interviewer name], and I'm calling to speak with [participant

More information

The Muscatine Study Heart Health Survey

The Muscatine Study Heart Health Survey The Muscatine Study Heart Health Survey PARTICIPANT ID LABEL (include study ID, name, DOB, gender) Today s Date: - - (MM-DD-YYYY) Thank you for agreeing to participate in the International Childhood Cardiovascular

More information

Common Repatha Documentation Requirements for Patients With Primary Hyperlipidemia and Established CVD 1,2

Common Repatha Documentation Requirements for Patients With Primary Hyperlipidemia and Established CVD 1,2 Established CVD Common Repatha Documentation Requirements for Patients With Primary Hyperlipidemia and Established CVD 1,2 Primary and Secondary Diagnosis Codes Primary Diagnosis: Primary hyperlipidemia

More information

Mediterranean Diet, Lifestyle Factors, and 10-Year Mortality -The HALE project-

Mediterranean Diet, Lifestyle Factors, and 10-Year Mortality -The HALE project- Mediterranean Diet, Lifestyle Factors, and 10-Year Mortality -The HALE project- Kim Knoops PhD-Student Wageningen University Supervisors: W.A. van Staveren C.P.G.M. de Groot D. Kromhout Outline of the

More information

Modelling Reduction of Coronary Heart Disease Risk among people with Diabetes

Modelling Reduction of Coronary Heart Disease Risk among people with Diabetes Modelling Reduction of Coronary Heart Disease Risk among people with Diabetes Katherine Baldock Catherine Chittleborough Patrick Phillips Anne Taylor August 2007 Acknowledgements This project was made

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Den Ruijter HM, Peters SA, Anderson TJ, et al. Common carotid intimamedia thickness measurements in cardiovascular risk prediction. JAMA. doi:10.1001/jama.2012.9630. etable

More information

Antihypertensive Trial Design ALLHAT

Antihypertensive Trial Design ALLHAT 1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes

More information

Date: / / Hello, my name is [interviewer name], and I'm calling to speak with [participant name]. Is [participant name] available?

Date: / / Hello, my name is [interviewer name], and I'm calling to speak with [participant name]. Is [participant name] available? Multi-Ethnic Study of Atherosclerosis Follow-up Phone Call 17 Participant Id#: Acrostic: General Health Date: / / Day INTRODUCTION Hello, my name is [interviewer name], and I'm calling to speak with [participant

More information

Alcohol s Good for You? Some Scientists Doubt It

Alcohol s Good for You? Some Scientists Doubt It Alcohol s Good for You? Some Scientists Doubt It By RONI CARYN RABIN Published: June 15, 2009 Pier Paolo Cito/Associated Press New York Times, Online Edition, June 15, 2009. A version of this article appeared

More information

INTEGRATED CHRONIC DISEASE PREVENTION

INTEGRATED CHRONIC DISEASE PREVENTION INTEGRATED CHRONIC DISEASE PREVENTION What Is Integrated Health Promotion? In this context, the term integrated health promotion refers to an approach to health and wellbeing that acknowledges that risk

More information

5. Cardiovascular Disease & Stroke

5. Cardiovascular Disease & Stroke 5. Cardiovascular Disease & Stroke 64: Self-Reported Heart Disease 66: Heart Disease Management 68: Heart Disease Mortality 70: Heart Disease Mortality Across Life Span 72: Stroke Mortality 185: Map 3:

More information

The Metabolic Syndrome: Is It A Valid Concept? YES

The Metabolic Syndrome: Is It A Valid Concept? YES The Metabolic Syndrome: Is It A Valid Concept? YES Congress on Diabetes and Cardiometabolic Health Boston, MA April 23, 2013 Edward S Horton, MD Joslin Diabetes Center Harvard Medical School Boston, MA

More information

Appendix S1. List of Figures. List of Tables

Appendix S1. List of Figures. List of Tables Appendix S1 List of Figures S1 Comparison of death rates in RealAge sample to US death rates...................... 1 S2 RealAge delta in California sample with full identifiers..........................

More information

TEN-YEAR ABSOLUTE RISK ESTImates

TEN-YEAR ABSOLUTE RISK ESTImates ORIGINAL CONTRIBUTION CLINICIAN S CORNER Lifetime Risk and Years Lived Free of Total Cardiovascular Disease Scan for Author Video Interview John T. Wilkins, MD, MS Hongyan Ning, MD, MS Jarett Berry, MD,

More information

Ulster, Ireland. Submitted: 21 June 2009; Revised: 24 January 2010; Published: 13 September 2010 Petrazzuoli F, Soler JK, Buono N, Dobbs F

Ulster, Ireland. Submitted: 21 June 2009; Revised: 24 January 2010; Published: 13 September 2010 Petrazzuoli F, Soler JK, Buono N, Dobbs F O R I G I N A L R E S E A R C H Quality of care for hypertensive patients with type 2 diabetes in a rural area of Southern Italy: is the recording of patient data and the achievement of quality indicators

More information

Vascular Diseases. Overview: Selected Slides

Vascular Diseases. Overview: Selected Slides Vascular Diseases Overview: Selected Slides Total deaths and change in vascular death rates

More information

FY 2011 WISEWOMAN Approved ICD-9 Code List

FY 2011 WISEWOMAN Approved ICD-9 Code List 243 Congenital hypothyroidism 245.0 Thyroiditis; Acute thyroiditis 245.1 Thyroiditis; Subacute thyroiditis 245.2 Thyroiditis; Chronic lymphocytic thyroiditis 245.3 Thyroiditis; Chronic fibrous thyroiditis

More information

1. The table shows the results of a blood test carried out on a patient who had suffered a heart attack. All units are arbitrary units.

1. The table shows the results of a blood test carried out on a patient who had suffered a heart attack. All units are arbitrary units. 1. The table shows the results of a blood test carried out on a patient who had suffered a heart attack. All units are arbitrary units. Substance Concentrations in patient s blood Normal range Cholesterol

More information

Original Contributions. Prospective Comparison of a Cohort With Asymptomatic Carotid Bruit and a Population-Based Cohort Without Carotid Bruit

Original Contributions. Prospective Comparison of a Cohort With Asymptomatic Carotid Bruit and a Population-Based Cohort Without Carotid Bruit 98 Original Contributions Prospective Comparison of a Cohort With Carotid Bruit and a Population-Based Cohort Without Carotid Bruit David O. Wiebers, MD, Jack P. Whisnant, MD, Burton A. Sandok, MD, and

More information

Table S1. Read and ICD 10 diagnosis codes for polymyalgia rheumatica and giant cell arteritis

Table S1. Read and ICD 10 diagnosis codes for polymyalgia rheumatica and giant cell arteritis SUPPLEMENTARY MATERIAL TEXT Text S1. Multiple imputation TABLES Table S1. Read and ICD 10 diagnosis codes for polymyalgia rheumatica and giant cell arteritis Table S2. List of drugs included as immunosuppressant

More information

Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study

Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study open access Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study Julia Hippisley-Cox, 1 Carol Coupland, 1 Peter Brindle

More information

Epidemiologic Measure of Association

Epidemiologic Measure of Association Measures of Disease Occurrence: Epidemiologic Measure of Association Basic Concepts Confidence Interval for population characteristic: Disease Exposure Present Absent Total Yes A B N 1 = A+B No C D N 2

More information

How would you manage Ms. Gold

How would you manage Ms. Gold How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56

More information

Table Cohort studies of consumption of alcoholic beverages and cancer of the colorectum

Table Cohort studies of consumption of alcoholic beverages and cancer of the colorectum Akhter et al. (2007), Japan, Miyagi Study [data also included in the pooled analysis, Mizoue et al. (2008)] of 21 199 men living in the Miyagi region recruited in 1990; aged 40 64 years; followed-up until

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Briefing paper QOF indicator area: Peripheral arterial disease Potential output:

More information

The Gender Divide Women, Men and Heart Disease February 2017

The Gender Divide Women, Men and Heart Disease February 2017 The Gender Divide Women, Men and Heart Disease February 2017 Nandita S. Scott, MD FACC Co-Director MGH Heart Center Corrigan Women s Heart Health Program Massachusetts General Hospital Heart Disease For

More information

Researchers prefer longitudinal panel data

Researchers prefer longitudinal panel data Pseudo-panel approach for repeated cross-sectional data - an introduction Yang Meng Sheffield Alcohol Research Group School of Health and Related Research University of Sheffield Researchers prefer longitudinal

More information

9/18/2017 DISCLOSURES. Consultant: RubiconMD. Research: Amgen, NHLBI OUTLINE OBJECTIVES. Review current CV risk assessment tools.

9/18/2017 DISCLOSURES. Consultant: RubiconMD. Research: Amgen, NHLBI OUTLINE OBJECTIVES. Review current CV risk assessment tools. UW MEDICINE UW MEDICINE UCSF ASIAN TITLE HEALTH OR EVENT SYMPOSIUM 2017 DISCLOSURES Consultant: RubiconMD ESTIMATING CV RISK IN ASIAN AMERICANS AND PREVENTION OF CVD Research: Amgen, NHLBI EUGENE YANG,

More information

rosuvastatin, 5mg, 10mg, 20mg, film-coated tablets (Crestor ) SMC No. (725/11) AstraZeneca UK Ltd.

rosuvastatin, 5mg, 10mg, 20mg, film-coated tablets (Crestor ) SMC No. (725/11) AstraZeneca UK Ltd. rosuvastatin, 5mg, 10mg, 20mg, film-coated tablets (Crestor ) SMC No. (725/11) AstraZeneca UK Ltd. 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product

More information

Recent developments in mortality

Recent developments in mortality Recent developments in mortality Richard Willets Willets Consulting Recent developments in mortality Patterns of aggregate mortality change Underlying causes Heart disease Lung cancer Other cancers Patterns

More information